Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 5 | 2025 | 1263 | 1.930 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2024 | 328 | 1.260 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 916 | 1.020 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2025 | 9373 | 0.920 |
Why?
|
Ependymoma | 2 | 2023 | 310 | 0.820 |
Why?
|
Spinal Cord Neoplasms | 1 | 2023 | 258 | 0.730 |
Why?
|
Glioma | 8 | 2025 | 3493 | 0.720 |
Why?
|
Paget Disease, Extramammary | 1 | 2021 | 52 | 0.720 |
Why?
|
Brain Neoplasms | 11 | 2025 | 9071 | 0.690 |
Why?
|
Photons | 2 | 2020 | 572 | 0.670 |
Why?
|
Skin Neoplasms | 4 | 2024 | 5849 | 0.670 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2022 | 480 | 0.650 |
Why?
|
Medulloblastoma | 2 | 2020 | 658 | 0.610 |
Why?
|
Radiotherapy | 2 | 2023 | 1494 | 0.580 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2018 | 52 | 0.580 |
Why?
|
Tumor Escape | 1 | 2020 | 371 | 0.570 |
Why?
|
Hematologic Diseases | 1 | 2020 | 500 | 0.540 |
Why?
|
Radiotherapy Dosage | 7 | 2024 | 2865 | 0.530 |
Why?
|
Vascular Malformations | 2 | 2021 | 471 | 0.510 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2021 | 784 | 0.510 |
Why?
|
Hyperpigmentation | 1 | 2017 | 117 | 0.510 |
Why?
|
Cerebellar Neoplasms | 1 | 2020 | 571 | 0.510 |
Why?
|
Radiation Oncology | 1 | 2022 | 569 | 0.500 |
Why?
|
Child | 27 | 2025 | 80564 | 0.490 |
Why?
|
Radiosurgery | 2 | 2021 | 1328 | 0.480 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1009 | 0.480 |
Why?
|
Capillaries | 1 | 2017 | 755 | 0.460 |
Why?
|
Sarcoma | 2 | 2023 | 1802 | 0.460 |
Why?
|
Leukemia | 1 | 2022 | 1522 | 0.440 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1050 | 0.430 |
Why?
|
Retrospective Studies | 22 | 2025 | 81514 | 0.420 |
Why?
|
Mitochondrial Proteins | 3 | 2015 | 975 | 0.420 |
Why?
|
Alopecia | 1 | 2017 | 414 | 0.420 |
Why?
|
Meningeal Neoplasms | 1 | 2021 | 1252 | 0.400 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1404 | 0.390 |
Why?
|
Graft vs Host Disease | 2 | 2022 | 3078 | 0.390 |
Why?
|
Germinoma | 2 | 2022 | 124 | 0.360 |
Why?
|
Neoplasms | 9 | 2023 | 22340 | 0.350 |
Why?
|
Abnormalities, Multiple | 1 | 2017 | 1424 | 0.340 |
Why?
|
Cell Cycle Proteins | 2 | 2019 | 3430 | 0.340 |
Why?
|
Amyotrophic Lateral Sclerosis | 3 | 2015 | 1484 | 0.340 |
Why?
|
Motor Neurons | 1 | 2015 | 869 | 0.330 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 3946 | 0.330 |
Why?
|
Palliative Care | 1 | 2025 | 3645 | 0.330 |
Why?
|
Child, Preschool | 12 | 2025 | 42500 | 0.320 |
Why?
|
Adolescent | 17 | 2025 | 88835 | 0.320 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2942 | 0.300 |
Why?
|
Vincristine | 2 | 2020 | 1039 | 0.290 |
Why?
|
Craniotomy | 3 | 2016 | 730 | 0.280 |
Why?
|
Nuclear Proteins | 3 | 2019 | 5783 | 0.270 |
Why?
|
Antioxidants | 1 | 2015 | 1670 | 0.270 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2022 | 5753 | 0.260 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2567 | 0.260 |
Why?
|
Humans | 50 | 2025 | 765968 | 0.260 |
Why?
|
Young Adult | 13 | 2024 | 59889 | 0.240 |
Why?
|
Immunotherapy | 1 | 2020 | 4752 | 0.230 |
Why?
|
Temporal Muscle | 1 | 2023 | 36 | 0.220 |
Why?
|
Growth Charts | 1 | 2023 | 60 | 0.210 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5389 | 0.210 |
Why?
|
Female | 29 | 2025 | 396112 | 0.200 |
Why?
|
Busulfan | 1 | 2022 | 264 | 0.180 |
Why?
|
Pineal Gland | 1 | 2022 | 153 | 0.180 |
Why?
|
Sturge-Weber Syndrome | 1 | 2022 | 88 | 0.180 |
Why?
|
Choroid Neoplasms | 1 | 2022 | 175 | 0.180 |
Why?
|
Whole-Body Irradiation | 1 | 2022 | 438 | 0.180 |
Why?
|
Male | 26 | 2025 | 363698 | 0.180 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13451 | 0.180 |
Why?
|
Mutation | 4 | 2022 | 30198 | 0.170 |
Why?
|
Hemangioendothelioma | 1 | 2021 | 112 | 0.170 |
Why?
|
Prognosis | 5 | 2025 | 29922 | 0.170 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.170 |
Why?
|
Infant | 6 | 2025 | 36386 | 0.170 |
Why?
|
Sex Reassignment Surgery | 1 | 2023 | 164 | 0.170 |
Why?
|
Ribonuclease III | 1 | 2022 | 269 | 0.170 |
Why?
|
Blood Cell Count | 1 | 2020 | 405 | 0.170 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 42 | 0.160 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2020 | 106 | 0.160 |
Why?
|
Lymphatic Abnormalities | 1 | 2021 | 134 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11868 | 0.160 |
Why?
|
Teratoma | 1 | 2022 | 401 | 0.160 |
Why?
|
Relative Biological Effectiveness | 1 | 2020 | 299 | 0.160 |
Why?
|
Pyrans | 1 | 2019 | 47 | 0.160 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 384 | 0.160 |
Why?
|
Morpholines | 2 | 2019 | 577 | 0.160 |
Why?
|
Cranial Irradiation | 1 | 2021 | 385 | 0.160 |
Why?
|
Infratentorial Neoplasms | 1 | 2019 | 94 | 0.150 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 869 | 0.150 |
Why?
|
Tattooing | 1 | 2018 | 56 | 0.150 |
Why?
|
Testicular Neoplasms | 2 | 2022 | 786 | 0.150 |
Why?
|
Sarcoma, Kaposi | 1 | 2021 | 375 | 0.140 |
Why?
|
Hemangioma | 1 | 2022 | 723 | 0.140 |
Why?
|
Dermatitis, Contact | 1 | 2017 | 135 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 616 | 0.130 |
Why?
|
Melanoma, Experimental | 1 | 2020 | 558 | 0.130 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 8529 | 0.130 |
Why?
|
Transplantation, Homologous | 2 | 2022 | 4860 | 0.130 |
Why?
|
Patient Positioning | 1 | 2018 | 328 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2025 | 39193 | 0.130 |
Why?
|
Oxidative Stress | 3 | 2015 | 3141 | 0.130 |
Why?
|
Radiotherapy, Conformal | 1 | 2018 | 533 | 0.120 |
Why?
|
Gender Identity | 1 | 2021 | 766 | 0.120 |
Why?
|
Arm | 1 | 2017 | 589 | 0.120 |
Why?
|
RNA-Binding Protein FUS | 1 | 2015 | 76 | 0.110 |
Why?
|
Brain Stem | 1 | 2019 | 853 | 0.110 |
Why?
|
Central Nervous System | 1 | 2021 | 1341 | 0.110 |
Why?
|
Adaptive Immunity | 1 | 2019 | 734 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 915 | 0.110 |
Why?
|
Histone Deacetylases | 1 | 2018 | 708 | 0.110 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 1643 | 0.110 |
Why?
|
Immune Tolerance | 2 | 2020 | 2324 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2017 | 540 | 0.110 |
Why?
|
NF-kappa B | 2 | 2020 | 2485 | 0.100 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 777 | 0.100 |
Why?
|
Serum Albumin | 1 | 2016 | 675 | 0.100 |
Why?
|
Carrier Proteins | 2 | 2016 | 4913 | 0.100 |
Why?
|
Treatment Outcome | 7 | 2022 | 65188 | 0.100 |
Why?
|
Leg | 1 | 2017 | 1080 | 0.100 |
Why?
|
Pyrimidines | 2 | 2022 | 3047 | 0.100 |
Why?
|
Quality Improvement | 3 | 2016 | 3853 | 0.100 |
Why?
|
Rare Diseases | 1 | 2017 | 635 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1181 | 0.100 |
Why?
|
Adult | 9 | 2023 | 223044 | 0.100 |
Why?
|
Mucous Membrane | 1 | 2015 | 657 | 0.100 |
Why?
|
Radiation Dosage | 1 | 2020 | 1944 | 0.090 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1635 | 0.090 |
Why?
|
Postoperative Complications | 4 | 2018 | 15747 | 0.090 |
Why?
|
Macrophages | 3 | 2023 | 5772 | 0.090 |
Why?
|
Barrett Esophagus | 1 | 2015 | 494 | 0.090 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6832 | 0.090 |
Why?
|
Recurrence | 1 | 2023 | 8501 | 0.090 |
Why?
|
Risk Assessment | 4 | 2025 | 24282 | 0.090 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6364 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6499 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1471 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 4 | 2025 | 36532 | 0.080 |
Why?
|
Neuroprotective Agents | 1 | 2015 | 959 | 0.080 |
Why?
|
Prospective Studies | 4 | 2021 | 54802 | 0.080 |
Why?
|
Time Factors | 3 | 2020 | 40065 | 0.080 |
Why?
|
DNA Damage | 1 | 2018 | 2457 | 0.070 |
Why?
|
Sepsis | 1 | 2022 | 2606 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1171 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2531 | 0.070 |
Why?
|
Massachusetts | 1 | 2021 | 8875 | 0.070 |
Why?
|
Evolution, Molecular | 1 | 2015 | 1889 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1646 | 0.070 |
Why?
|
Animals | 11 | 2023 | 168764 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2339 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10070 | 0.060 |
Why?
|
Cell Survival | 1 | 2015 | 5747 | 0.060 |
Why?
|
Databases, Factual | 2 | 2017 | 8067 | 0.060 |
Why?
|
Esophageal Neoplasms | 1 | 2015 | 1661 | 0.060 |
Why?
|
Disease Models, Animal | 4 | 2019 | 18293 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2054 | 0.060 |
Why?
|
Aged | 6 | 2024 | 171117 | 0.060 |
Why?
|
Mice, Inbred C57BL | 3 | 2020 | 22332 | 0.060 |
Why?
|
Mice | 9 | 2023 | 81819 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4044 | 0.050 |
Why?
|
Incidence | 2 | 2019 | 21480 | 0.050 |
Why?
|
Mice, Transgenic | 1 | 2015 | 9550 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16721 | 0.050 |
Why?
|
Uridine | 1 | 2022 | 135 | 0.050 |
Why?
|
Signal Transduction | 3 | 2020 | 23601 | 0.050 |
Why?
|
Mice, Nude | 2 | 2019 | 3618 | 0.050 |
Why?
|
Transcription Factors | 2 | 2019 | 12131 | 0.050 |
Why?
|
Length of Stay | 1 | 2015 | 6485 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1885 | 0.050 |
Why?
|
Disease Progression | 2 | 2015 | 13632 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2021 | 26346 | 0.040 |
Why?
|
Anal Canal | 1 | 2023 | 376 | 0.040 |
Why?
|
Proteins | 1 | 2015 | 5995 | 0.040 |
Why?
|
Cerebral Cortex | 1 | 2016 | 5767 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 13462 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15880 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 223009 | 0.040 |
Why?
|
Aged, 80 and over | 1 | 2024 | 59489 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 13039 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 9601 | 0.040 |
Why?
|
Vagina | 1 | 2023 | 848 | 0.040 |
Why?
|
Protons | 1 | 2022 | 1073 | 0.030 |
Why?
|
Azepines | 1 | 2019 | 327 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 17075 | 0.030 |
Why?
|
Neurons | 1 | 2016 | 9525 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 26318 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2020 | 728 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2018 | 347 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 862 | 0.030 |
Why?
|
Cell Polarity | 1 | 2019 | 636 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1617 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 2453 | 0.030 |
Why?
|
INDEL Mutation | 1 | 2015 | 268 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2056 | 0.030 |
Why?
|
Standard of Care | 1 | 2019 | 567 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2020 | 11022 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2023 | 2878 | 0.030 |
Why?
|
Triazoles | 1 | 2019 | 897 | 0.030 |
Why?
|
Preoperative Period | 1 | 2016 | 566 | 0.030 |
Why?
|
Integrases | 1 | 2016 | 520 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2015 | 924 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 782 | 0.030 |
Why?
|
Interleukin-13 | 1 | 2015 | 388 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2015 | 446 | 0.030 |
Why?
|
GTPase-Activating Proteins | 1 | 2015 | 465 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14751 | 0.020 |
Why?
|
Methylation | 1 | 2015 | 1073 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6113 | 0.020 |
Why?
|
Movement | 1 | 2018 | 1462 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2024 | 3356 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3608 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2015 | 1162 | 0.020 |
Why?
|
Arginine | 1 | 2015 | 933 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13266 | 0.020 |
Why?
|
Mitosis | 1 | 2016 | 1173 | 0.020 |
Why?
|
Survival Rate | 1 | 2025 | 12795 | 0.020 |
Why?
|
Cytoplasm | 1 | 2015 | 1500 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18380 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2910 | 0.020 |
Why?
|
RNA Splicing | 1 | 2015 | 903 | 0.020 |
Why?
|
Intracranial Hemorrhages | 1 | 2016 | 814 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6220 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2015 | 1718 | 0.020 |
Why?
|
Age of Onset | 1 | 2017 | 3344 | 0.020 |
Why?
|
Thalamus | 1 | 2016 | 1048 | 0.020 |
Why?
|
Neurogenesis | 1 | 2016 | 866 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2048 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2015 | 3750 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2015 | 1314 | 0.020 |
Why?
|
Axons | 1 | 2016 | 1682 | 0.020 |
Why?
|
Spinal Cord | 1 | 2016 | 1784 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7232 | 0.020 |
Why?
|
Program Evaluation | 1 | 2016 | 2499 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5696 | 0.020 |
Why?
|
Autophagy | 1 | 2015 | 1351 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8041 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2016 | 2428 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15842 | 0.020 |
Why?
|
Reoperation | 1 | 2016 | 4294 | 0.020 |
Why?
|
Patient Selection | 1 | 2017 | 4255 | 0.010 |
Why?
|
Computer Simulation | 1 | 2018 | 6255 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3925 | 0.010 |
Why?
|
Overweight | 1 | 2016 | 2444 | 0.010 |
Why?
|
Skin | 1 | 2018 | 4489 | 0.010 |
Why?
|
Cytokines | 1 | 2020 | 7421 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4893 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10429 | 0.010 |
Why?
|
Cell Movement | 1 | 2016 | 5194 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2016 | 3212 | 0.010 |
Why?
|
Apoptosis | 1 | 2020 | 9514 | 0.010 |
Why?
|
Chronic Disease | 1 | 2018 | 9347 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3475 | 0.010 |
Why?
|
Protein Binding | 1 | 2015 | 9296 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7584 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15543 | 0.010 |
Why?
|
Patient Readmission | 1 | 2015 | 3286 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10563 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12509 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7599 | 0.010 |
Why?
|
Risk Factors | 2 | 2018 | 74840 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11206 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8297 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15398 | 0.010 |
Why?
|
United States | 2 | 2018 | 72903 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20124 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20659 | 0.010 |
Why?
|